Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

19.03.2025

Oxford BioTherapeutics Announces That Partner Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody-Based Cancer Treatments

09.01.2025

Oxford BioTherapeutics To Present at World ADC Conference 2024

30.10.2024

Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 2024

22.07.2024

Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

07.03.2024

Oxford BioTherapeutics Announces First Patient Dosed With OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

18.01.2024

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

29.11.2023

Oxford BioTherapeutics Announced Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial With BI 764532 in Small Cell Lung Cancer and Other Neuroendocrine Cancers

24.10.2023

Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at the Oxford Science Park To Accelerate Development of Its Immuno-Oncology and ADC-Based Cancer Therapies

11.10.2023

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers​

03.10.2023

Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim's upcoming Transforming Science Day: Europe ​​

19.09.2023

Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumours by Dosing First Patient in Combination with CPI Balstilimab in Europe ​

05.07.2023

Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology

25.05.2023

Oxford BioTherapeutics Announces Phase1b Trial in Collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the Head and Neck

19.04.2023

Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at the World ADC Conference 2023

09.03.2023

Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards

07.03.2023

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

13.06.2022

Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

13.06.2022

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

27.05.2022

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in Combination with Agenus CPI Balstilimab

25.05.2022

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology target

13.04.2022

AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076

07.04.2022

Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic

20.09.2021

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform

19.01.2021

Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours

06.01.2021

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

14.10.2020

Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors ​

09.01.2020

Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate

25.06.2019

Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients

21.12.2018

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

11.12.2018

​Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director

13.06.2017

Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans​​​​​

09.02.2017

Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics​​

26.01.2017

Boehringer Ingelheim Exercises Option on Second Oncology Target using Oxford BioTherapeutics’ OGAP® System​

18.04.2016

Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates

04.04.2016